This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Berenberg Bank Remains a Buy on Novo Nordisk (0QIU)

Tipranks - Tipranks - Thu Jun 18, 2:38AM CDT

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Novo Nordisk today and set a price target of DKK325.00.

Claim 55% Off TipRanks

Holford covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Eli Lilly & Co, and Pfizer. According to TipRanks, Holford has an average return of 8.1% and a 53.61% success rate on recommended stocks.

The word on The Street in general, suggests a Hold analyst consensus rating for Novo Nordisk with a DKK279.73 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Novo Nordisk’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of DKK96.82 billion and a net profit of DKK48.56 billion. In comparison, last year the company earned a revenue of DKK78.09 billion and had a net profit of DKK29.03 billion

Read More on GB:0QIU:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).